TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7604754
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate sugar coated tablet
Study: 7604754
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride (IV infusion)
Study: 3075630
Drug: Pheniramine maleate
Normalized name: Pheniramine Maleate
DrugBank: Pheniramine (DB01620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pheniramine maleate (supplement) for the first 3 months
Study: 3075630
Drug: Clofazimine and
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine and dapsone (control) for 12 months without supplement
Study: 19025407
Drug: 830-nm diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 830-nm diode laser treatment (10 Hz, 50% duty cycle, 60 mW, 9.7 J/cm²) for 2 weeks, 10-min sessions, 5 days a week
Study: 19025407
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham laser treatment)
Study: 19025407
Drug: 830-nm diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 830-nm diode laser treatment
Study: 11015032
Drug: Zolpidem 8.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 8.03 mg
Study: 11015032
Drug: Zolpidem 16.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 16.06 mg
Study: 9445577
Drug: Dipotassium clorazepate
Normalized name: Dipotassium clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassium clorazepate 10 mg
Study: 9445577
Drug: Dipotassium clorazepate
Normalized name: Dipotassium clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassium clorazepate 20 mg
Study: 30169405
Drug: Neostigmine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 20 μg/kg and atropine 10 μg/kg
Study: 18166839
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus cisplatin 80 mg/m2 on day 1 (GC)
Study: 18166839
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (GP)
Study: 18166839
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (GCb)
Study: 18166839
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with gemcitabine (all regimens)
Study: 15560162
Drug: Viagra (individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra (individually adjusted dose for 6 months)
Study: 15560162
Drug: Sialis (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sialis (20 mg for 6 months)
Study: 15560162
Drug: Impase (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impase (1 tablet every other day sublingually for 6 months)
Study: 15560162
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDE‐5 inhibitors (Viagra, Sialis) and Impase
Study: 8477555
Drug: Oral racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral racemic ibuprofen (400 mg)
Study: 8477555
Drug: Intravenous racemic
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous racemic ibuprofen (60-minute infusion)
Study: 22854639
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (75 µg or 3,000 IU per day)
Study: 20231324
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Naltrexone (200 mg/day + 100 mg/day)
Study: 7969211
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg/day)
Study: 15767536
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (100 mg) every other week by intramuscular injection
Study: 15767536
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent volume) every other week by intramuscular injection
Study: 22210925
Drug: Orlistat (lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (lipase inhibitor)
Study: 11729638
Drug: Alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-glucosidase inhibitors (inhibitors of carbohydrate absorption)
Study: 9041328
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups in mean plasma RNA level
Study: 7523914
Drug: Chronic exposure
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic exposure to arsenic via drinking water (412 micrograms/l)
Study: 7523914
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drinking water with arsenic average levels of 37.2 micrograms/l)
Study: 3452274
Drug: Caffeine (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (230 mg)
Study: 27213613
Drug: Lancet weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lancet weight of 25 g
Study: 27213613
Drug: Lancet weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lancet weight of 85 g
Study: 27213613
Drug: Lancet weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lancet weight of 135 g
Study: 27213613
Drug: Lancet weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lancet weight of 265 g
Study: 27213613
Drug: Histamine 1
Normalized name: Antihistamine 12 Hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine 1 mg/mL (positive control)
Study: 27213613
Drug: Histamine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine 10 mg/mL (positive control)
Study: 19202157
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily (n = 118)
Study: 17005362
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg of etomidate (priming group)
Study: 15316868
Drug: Etidronate 200
Normalized name: etidronate 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 200 mg/day (intermittent treatment)
Study: 11736716
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (6 mg twice daily, increasing to 9 mg twice daily after 6 weeks)
Study: 9522321
Drug: HRT (hormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (hormonal replacement therapy) as oral or transdermal oestradiol supplemented with progestogen
Study: 9522321
Drug: Oral sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sequential oestrogen plus progestogen
Study: 3047394
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (1.5 mg/2.5 cm2)
Study: 29254669
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1.5 mg/kg)
Study: 25027194
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (0.1 mg/kg)
Study: 21698591
Drug: Intra-articular infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular infiltration of 10 ml of 0.25% bupivacaine
Study: 21698591
Drug: Portal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portal infiltration of 10 ml of 0.25% bupivacaine
Study: 52001
Drug: Urokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase and Glucose infusion
Study: 29246820
Drug: Standard-dose filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose filgrastim (10 µg/kg BW per day)
Study: 29246820
Drug: Reduced-dose filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose filgrastim (5 µg/kg BW per day)
Study: 23172749
Drug: Etanercept (ETA)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETA) treatment for 1 year
Study: 16926353
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (333 U/kg initial dose, followed by 250 U/kg every 12 hours)
Study: 16926353
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (100 IU/kg every 12 hours)
Study: 12953129
Drug: G‐CSF mobilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF mobilized PB and BM
Study: 12953129
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and GM‐CSF mobilized grafts
Study: 12953129
Drug: G‐CSF stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF stimulated PB
Study: 10899449
Drug: Catalyzed Signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catalyzed Signal Amplification system with DYS1 and DYS2 antibodies
Study: 10899449
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients with DYS1 and DYS2 antibodies
Study: 6609933
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 0.5 mg/kg/day for 7 days
Study: 6609933
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1.0 mg/kg (single injection)
Study: 30098822
Drug: Combined Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Manual Therapy (MT) and Diadynamic (DD) currents (MTDD)
Study: 30098822
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MT) alone
Study: 16968874
Drug: Epirubicin (E)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (E) 110 mg/m2 followed by paclitaxel (P) 250 mg/m2 followed by intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2)
Study: 15882216
Drug: Transmucosal anaesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmucosal anaesthetic patches containing lidocaine (46.1 mg/2 cm(2))
Study: 9391998
Drug: Ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (600 mg/day) plus calcium (500 mg/day)
Study: 9391998
Drug: Ipriflavone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (400 mg/day) plus conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Study: 9391998
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Study: 3308571
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of cefoxitin (2 g)
Study: 3308571
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of cefoxitin (2 g, 1 g, and 1 g)
Study: 26427705
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg qid on day 0 and bid on days 1 to 7
Study: 26427705
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg bid for 7 days
Study: 26427705
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg qid for 7 days
Study: 26427705
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg bid in IMs
Study: 26427705
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg bid in PMs
Study: 24174910
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block using 1 mL·kg(‐1) lidocaine (1%) after 2 mg·kg(‐1) ketamine IV
Study: 24174910
Drug: 2 mg·kg(‐1) ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg·kg(‐1) ketamine IV only
Study: 16555144
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment controls
Study: 27744007
Drug: NO3−-rich beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO3−-rich beetroot juice (140 mL day−1; 8.4 mmol NO3− day−1)
Study: 20884893
Drug: Control (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (delayed evaluation or treatment for 6 months)
Study: 18186976
Drug: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) administered with a 12-h or 24-h interval between tablets.
Study: 16338010
Drug: OxLDL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxLDL levels >76 U/L
Study: 16338010
Drug: OxLDL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxLDL levels >76 U/L in TnT negative group
Study: 16338010
Drug: OxLDL levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxLDL levels ≤76 U/L
Study: 8616946
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg orally twice daily for 14 days)
Study: 1917227
Drug: Nandrolone-decanoate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone-decanoate (100 mg weekly i.m. injection)
Study: 7050440
Drug: Special Intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special Intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels
Study: 3873785
Drug: Bypass surgery
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bypass surgery (beta blockers)
Study: 27516093
Drug: Utidelone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utidelone (25 to 35 mg/m2/day intravenously infused once daily for 5 days) in combination with capecitabine (2000 mg/m2 divided in two equal daily oral doses for 14 days)
Study: 27516093
Drug: Utidelone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utidelone (40 mg/m2/day intravenously infused once daily for 5 days) as monotherapy
Study: 6270998
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber diet (59 g neutral detergent fiber)
Study: 6270998
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (21 g neutral detergent fiber)
Study: 6270998
Drug: Low fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fiber diet (21 g neutral detergent fiber)
Study: 18160763
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB) - 50 mg of losartan potassium administered once daily for one year
Study: 15886228
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (6 mg)
Study: 10785238
Drug: 100 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Study: 10785238
Drug: 150 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Study: 11922560
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg once daily
Study: 9301500
Drug: Budesonide 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 4.5 mg twice daily
Study: 9301500
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg once daily
Study: 8280824
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg q.d.s., 7 days)
Study: 8280824
Drug: Liquid Gaviscon
Normalized name: Gaviscon Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Gaviscon (sodium alginate compound)
Study: 3552444
Drug: Cryoprecipitate infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cryoprecipitate infusion
Study: 23449130
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a mixture of Trifolium pratense flower extract and a biomimetic peptide
Study: 21593619
Drug: Twice-weekly peginterferon-α-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-weekly peginterferon-α-2a 180 μg/week (for 4 weeks, followed by weekly dosing) and weight-based ribavirin (1-1.2 g/day)
Study: 21593619
Drug: Weekly peginterferon-α-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly peginterferon-α-2a 180 μg/week and weight-based ribavirin (1-1.2 g/day)
Study: 19619692
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (UFH) bolus 70 IU/kg
Study: 19619692
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin (1 mg/kg every 12 hours for 2.5 days)
Study: 11044536
Drug: Prostaglandin E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(2) intravaginal gel (2 mg)
Study: 11044536
Drug: Prostaglandin E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(2) intracervical gel (0.5 mg)
Study: 3525584
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control (NTC)
Study: 27914492
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (90 mg twice daily) plus low-dose aspirin (81-100 mg daily) for 3 months, then ticagrelor plus placebo for 12 months
Study: 27914492
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus low-dose aspirin (81-100 mg daily) for 3 months, then continuation of ticagrelor plus aspirin
Study: 25618415
Drug: GEMOXEL (GEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOXEL (GEM 1,000 mg/m², L-OHP 100 mg/m², CAP 1,500 mg/m²/day)
Study: 25618415
Drug: GEM (GEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM (GEM 1,000 mg/m²)
Study: 24524600
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (n = 70)
Study: 21943132
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal therapy involving removal of subgingival and supragingival calculus and plaque biofilm by scaling and root‐planing.
Study: 16530290
Drug: IFN-alpha treatment
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha treatment in CHB patients
Study: 16530290
Drug: IFN-alpha treatment
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha treatment in CHC patients
Study: 10613766
Drug: Purple grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple grape juice (5-7.5 mL/(kg. d) for 7-10 days)
Study: 10613766
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (5-7.5 mL/(kg. d) for 7-10 days)
Study: 10613766
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (5-7.5 mL/(kg. d) for 7-10 days)
Study: 2923769
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.25% bupivacaine through an extradural catheter
Study: 2923769
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.25% bupivacaine through a paravertebral catheter
Study: 29079990
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (2 × 10^9 CFU/g each of Lactobacillus acidophilus strain T16, Lactobacillus casei strain T2, and Bifidobacterium bifidum strain T1 plus 800 mg inulin)
Study: 29103871
Drug: Olaparib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (100 mg twice daily) plus paclitaxel (80 mg/m2 intravenously)
Study: 29103871
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus paclitaxel (80 mg/m2 intravenously)
Study: 17541058
Drug: Cortisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone (25 mg)
Study: 17541058
Drug: Cortisone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone (25 mg) + Propranolol (40 mg)
Study: 2205962
Drug: Early occupational
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early occupational therapy (1-3 days after injury)
Study: 6107722
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of acetylsalicylic acid